Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 2 of 8812345...102030...Last »

Tricida Reports Positive Pivotal Phase 3 Study Results

Tricida Inc. announced results from its pivotal Phade 3 clinical trial for TRCA-301 in 217 chronic kidney disease patients with metabolic acidosis.

Read More »

Merck’s Keytruda shows promise in treating advanced melanoma

Merck & Co. Inc. said long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment.

Read More »

Mixed study results for cancer drug combo

Mixed results were reported from closely watched studies combining Bristol-Myers Squibb’s cancer immunotherapy Opdivo with Nektar Therapeutics’ experimental drug NKTR-214.

Read More »

Keytruda extends lung cancer survival in two trials

Merck & Co.’s immunotherapy Keytruda improved survival as a stand-alone treatment for newly diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer.

Read More »

Many women with early-stage breast cancer can skip chemotherapy: study

Some 70 percent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can safely skip chemotherapy after tumor removal, U.S. researchers said.

Read More »

Roche drugs show limited benefit in lung, breast cancer trialsd

In a disappointment for Roche Holding, two of its oncology drugs provided only modest protection from disease progression in lung cancer and breast cancer, according to data from separate clinical trials.

Read More »

Esketamine Shows Promise in Depression Studies

Janssen, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray in patients with treatment-resistant depression.

Read More »

Madrigal Pharma reports liver drug study success

Madrigal Pharmaceuticals’ shares more than doubled after mid-stage trial data showed the company’s lead drug reduced liver fat in patients with fatty liver disease.

Read More »

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

AstraZeneca’s first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Read More »

Novo Nordisk’s oral diabetes drug beats Jardiance in study

Novo Nordisk said data from a large final-stage study of a pill the company hopes will transform the diabetes market proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim’s established Jardiance.

Read More »

Genmab, Johnson & Johnson Halt Lung Cancer Study

Genmab and J&J’s Janssen division pulled the plug on the Phase Ib/II trial of daratumumab in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced or metastatic NSCLC.

Read More »

Roche notches another lung cancer win

Roche’s bid to keep Merck’s cancer blockbuster Keytruda within striking distance got a lift when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients’ survival.

Read More »

AstraZeneca cancer drug hits second goal by extending survival

AstraZeneca’s immunotherapy drug Imfinzi hit a second important goal by improving overall survival in lung cancer patients.

Read More »

Keytruda succeeds in late-stage lung cancer study

Merck & Co.’s cancer drug Keytruda helped extend survival and prevented disease progression when tested in a late-stage study in combination with chemotherapy for a type of lung cancer.

Read More »

Sesen Bio Shares Plunge Despite Reporting Positive Interim Phase III Results

Shares of newly dubbed Sesen Bio plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer trial.

Read More »

Nabriva shares tumble as safety worries plague pneumonia drug

Nabriva Therapeutics Plc’s potential new antibiotic to treat a common form of pneumonia met the main goal of a key clinical trial.

Read More »

Roche drug dramatically reduces bleeds in key hemophilia tests

Roche’s recently launched medicine Hemlibra dramatically reduced bleeding in a broad population of hemophilia patients, results from two clinical trials showed.

Read More »

J&J Ends Early Alzheimer’s Program

Johnson & Johnson’s Janssen division decided to end clinical trials of atabacestat, a BACE inhibitor, for Alzheimer’s disease.

Read More »

Alecensa Beats Out Xalkori in Late-Stage Study

Genentech, a Roche company, released follow-up data from its Phase III ALEX trial comparing its Alecensa (alectinib) to Pfizer’s Xalkori (crizotinib) in late-stage non-small cell lung cancer.

Read More »

AstraZeneca’s drug Fasenra flops in COPD trial

AstraZeneca’s first respiratory biologic medicine Fasenra failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Read More »

Page 2 of 8812345...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review

Subscribe

Ad Right Bottom

Main Navigation